Clearmind Medicine Inc. (CMND)
NASDAQ: CMNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CMND stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.33M
- EPS (TTM)
- -$461.20
- Dividend yield
- None
- 52-week range
- 2.63 – 649.60
- Day range
- 2.63 – 3.28
- Volume / Avg
- 9.84K / 55.57K
- Beta
- —
- Shares outstanding
- 507.40K
52-week range
CMND stock today
Shares of Clearmind Medicine (CMND) finished lower on Nov 20 at $2.63, a drop of 17.68% or $0.5649 per share, versus the S&P 500's 3.70% decline. Trading was light, with 9.84K shares changing hands, about 18% of the average daily volume. At this level, CMND sits near the bottom of its 52-week range of $2.63 to $649.60: 99.6% below the high and 0.0% above the low.
Clearmind Medicine has posted a net loss over the last twelve months (EPS of -$461.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Clearmind Medicine
Company profileClearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Adi Zuloff-Shani Ph.D.
- Headquarters
- Vancouver, BC
- Website
- clearmindmedicine.com
Financial highlights
Full financialsClearmind Medicine reported a net loss of $3.9 million, compared with a loss of $5.3 million a year earlier. Diluted earnings per share came in at -$30.35.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-3.86M | $-5.25M | $-8.62M | $-6.89M | $-2.73M |
| EPS (diluted) | $-30.35 | $-67.80 | $-1,703.04 | $-159.11 | $-88.16 |
CMND news
All CMND news- Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application PublicationGlobeNewswire
- Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical MilestoneGlobeNewswire
- Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic SummitGlobeNewswire
- Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical TrialGlobeNewswire
- Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous FleetsGlobeNewswire
- Clearmind Gains Japan Patent Coverage For 3-MMC And PEA CombinationNasdaqCMND, BRK.B
- Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement DisorderGlobeNewswire
Clearmind Medicine peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELABPMGC Holdings Inc. | 1.14 | -10.24% | $1.33M | vs CMND |
| CAPSCapstone Holding Corp. | 1.44 | -9.15% | $1.35M | vs CMND |
| ARTLArtelo Biosciences Inc. | 1.39 | -4.14% | $1.30M | vs CMND |
| APVOAptevo Therapeutics Inc. | 0.4041 | -2.37% | $1.40M | vs CMND |
| JUNSJupiter Neurosciences Inc. | 1.24 | -18.75% | $1.63M | vs CMND |
| PRFXPRF Technologies Ltd. | 0.4758 | -23.68% | $1.66M | vs CMND |
| GOVXGeoVax Labs Inc. | 1.81 | -5.24% | $985.46K | vs CMND |
| BDRXBiodexa Pharmaceuticals plc American Depositary Shs | 1.88 | -3.85% | $982.95K | vs CMND |
Indexes, lists and sector
Clearmind Medicine stock FAQ
What is Clearmind Medicine's stock price today?
CMND last traded at $2.63 as of Nov 20, 4:00 PM EST, down 17.68% on the day. Prices are delayed at least 15 minutes.
Who is Clearmind Medicine's CEO?
Dr. Adi Zuloff-Shani Ph.D. is the chief executive officer of Clearmind Medicine Inc..
What is the CMND 52-week high?
The 52-week high for CMND is $649.60 and the 52-week low is $2.63. The stock is currently 99.6% below its high.